Pre-IND application of GenAssist’s First DMD Drug was Accepted by the US FDA!
Recently, Suzhou GenAssisit Therapeutics Co.,Ltd. (hereinafter referred to as “GenAssist”) announced that its first base editing product, GEN6050, has submitted a pre-investigational new drug (Pre-IND) application to the FDA and has been accepted. GEN6050 is an in vivo base editing drug targeting exon 50 skipping for the treatment of Duchenne Muscular Dystrophy (DMD). The drug […]
Pre-IND application of GenAssist’s First DMD Drug was Accepted by the US FDA! Read More »
